Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease

Bram Verstockt(Universitair Ziekenhuis Leuven), Christine Breynaert(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Gert Van Assche(KU Leuven), Brecht Creyns(KU Leuven), Ann Gils(KU Leuven), Sare Verstockt(KU Leuven), Jan Ceuppens, Sophie Tops(KU Leuven), Séverine Vermeire(KU Leuven)
Alimentary Pharmacology & Therapeutics
January 20, 2019
10.1111/apt.15126
Cited by 72

Related Papers

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k